Clinical Trials Logo

Small Cell Lung Carcinoma clinical trials

View clinical trials related to Small Cell Lung Carcinoma.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06064500 Available - Clinical trials for Small Cell Lung Cancer

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen). EA may still be available in countries outside of the United States.

NCT ID: NCT04507919 Available - Clinical trials for Small Cell Lung Carcinoma

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of eligible patients diagnosed with BRAF V600E/K activating mutation-positive advanced NSCLC using trametinib/dabrafenib in the Cohort MAP CTMT212X2002I. The Physician should follow the suggested treatment guidelines. Furthermore, the Physician must comply with the MAP Agreement Letter and applicable local laws and regulations.

NCT ID: NCT01317953 Available - Clinical trials for Small Cell Lung Carcinoma

Oral Green Tea Extract for Small Cell Lung Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.